WSJ -- Pfizer Inc. is due to appear Monday before outside medical experts and Food and Drug Administration officials to make a case for allowing its Fablyn osteoporosis drug on the market. It will be the drug’s third go-round, and approval is important for a pharmaceutical company that, like its rivals, is eager to fill its new-product pipeline.
